Platinum Chemotherapy Hypersensitivity: Prevalence and Management

Area of Science:

• Oncology
• Clinical Immunology
• Pharmacology

Background:

• Hypersensitivity reactions (HSRs) to platinum-based chemotherapy agents are a frequent clinical challenge.
• The timing of HSRs differs among platinum agents: carboplatin and cisplatin typically cause reactions upon second or third re-exposure, while oxaliplatin reactions can occur anytime during treatment.

Purpose of the Study:

• To evaluate the utility of skin testing for risk stratification of patients experiencing hypersensitivity reactions to platinum agents.
• To assess the safety and efficacy of desensitization protocols in managing platinum agent hypersensitivity.

Main Methods:

• Utilized serial skin testing to stratify patient risk for hypersensitivity reactions.
• Implemented desensitization protocols for patients with confirmed platinum agent hypersensitivity.
• Monitored for breakthrough hypersensitivity reactions during desensitization.

Main Results:

• Skin testing effectively identifies patients at risk for hypersensitivity reactions.
• A structured protocol involving skin testing and desensitization allows for safe administration of platinum agents in hypersensitive patients.
• This approach enables patients to receive necessary first-line chemotherapy despite prior hypersensitivity.

Conclusions:

• Skin testing is a valuable tool for risk stratification in platinum agent hypersensitivity.
• Desensitization protocols, guided by risk stratification, enable safe chemotherapy delivery for patients with hypersensitivity.
• Managing hypersensitivity reactions through skin testing and desensitization improves treatment options for cancer patients.